Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Michetti

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Inflammatory Bowel Diseases|November 1, 2011
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus reportBrian G Feagan, Marc Lémann, Ragnar Befrits, et al.
Journal of Crohn'S & Colitis|February 14, 2012
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusWalter Reinisch, Gert Van Assche, Ragnar Befrits, et al.
Journal of Crohn'S & Colitis|December 22, 2010
European evidence-based Consensus on the management of ulcerative colitis: Special situationsLivia Biancone, Pierre Michetti, Simon Travis, et al.
Nature Medicine|January 22, 2019
Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
Nature Medicine|March 9, 2019
Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
European Journal of Gastroenterology & Hepatology|November 1, 2022
Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the diseaseMaude Martinho-Grueber, Ioannis Kapoglou, Francisco Bravo, et al.
Inflammatory Bowel Diseases|May 29, 2015
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease CohortStephan R Vavricka, Gerhard Rogler, Claudine Gantenbein, et al.
Journal of the Canadian Association of Gastroenterology|October 5, 2022
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of ResponseValerie Heron, Steven Li Fraine, Nicola Panaccione, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Inflammatory Intestinal Diseases|July 19, 2018
Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS)Ekaterina Safroneeva, Catherine Saner, Jean-Benoît Rossel, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Inflammatory Bowel Diseases|November 1, 2011
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus reportBrian G Feagan, Marc Lémann, Ragnar Befrits, et al.
Journal of Crohn'S & Colitis|February 14, 2012
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensusWalter Reinisch, Gert Van Assche, Ragnar Befrits, et al.
Journal of Crohn'S & Colitis|December 22, 2010
European evidence-based Consensus on the management of ulcerative colitis: Special situationsLivia Biancone, Pierre Michetti, Simon Travis, et al.
Nature Medicine|January 22, 2019
Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
Nature Medicine|March 9, 2019
Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's diseaseBahtiyar Yilmaz, Pascal Juillerat, Ove Øyås, et al.
European Journal of Gastroenterology & Hepatology|November 1, 2022
Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the diseaseMaude Martinho-Grueber, Ioannis Kapoglou, Francisco Bravo, et al.
Inflammatory Bowel Diseases|May 29, 2015
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease CohortStephan R Vavricka, Gerhard Rogler, Claudine Gantenbein, et al.
Journal of the Canadian Association of Gastroenterology|October 5, 2022
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of ResponseValerie Heron, Steven Li Fraine, Nicola Panaccione, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor AgentsPauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
Inflammatory Intestinal Diseases|July 19, 2018
Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS)Ekaterina Safroneeva, Catherine Saner, Jean-Benoît Rossel, et al.
Pageof 15